tralokinumab   Click here for help

GtoPdb Ligand ID: 8001

Synonyms: Adbry® | Adtralza® | BAK1.1 [2] | CAT-354 [2] | tralokinumab-ldrm
Approved drug Immunopharmacology Ligand
tralokinumab is an approved drug (EMA & FDA (2021))
Compound class: Antibody
Comment: Tralokinumab is a monoclonal antibody directed against interleukin 13 (IL-13), a cytokine secreted by T helper cells, and which is a central mediator of the physiological changes induced by allergic inflammatory reactions [4] Binding affinity of tralokinumab was optimised (aka affinity maturation) using an in vitro ribosome display technology [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-13 Primary target of this compound Hs Antibody Binding 9.8 pKd - 2
⤷ pKd 9.8 (Kd 1.64x10-10 M) [2]